Ziftomenib in Relapsed or Refractory <i>NPM1</i> -Mutated AMLJordi Esteve Reyner, Pau Montesinos, James M. Foran et al.|Journal of Clinical Oncology|2025Cited by 33
Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemiaJoaquín Martínez‐López, Juan Ballesteros, Pau Montesinos et al.|Medicine International|2022Cited by 4
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasmRoberta S. Azevedo, N. Pemmaraju, Zohra Nooruddin et al.|Expert Opinion on Biological Therapy|2025Cited by 0
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasmRoberta S. Azevedo, N. Pemmaraju, Zohra Nooruddin et al.|Figshare|2025Cited by 0
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasmRoberta S. Azevedo, N. Pemmaraju, Adolfo de la Fuente et al.|Figshare|2025Cited by 0